Fundraising FoxHatteras Venture Partners — 2020 Investments
6 investments dated 2020 · listed companies and verified rows first · show all
CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.
BiotechHealthtechMedical DevicesAustin, US
Craig Palmer(Executive Officer)inNadim Yared(Executive Officer, Director)inDean Bruhn-Ding(Executive Officer)inJohn Brintnall(Executive Officer)inLiz Galle(Executive Officer)Kevin Hykes(President, Chief Executive Officer & Director)in
Co-investorsABS VenturesNew Enterprise Associates (NEA)Treo Ventures, LlcWindham Capital PartnersYsios CapitalAction Potential Venture Capital Ltd.+1 more
Mercy BioAnalytics develops diagnostic tests for early cancer detection using advanced proteomics and genomics technologies.
BiotechDigital HealthHealthtechMedical DevicesNatick, US
Paul Blavin(Co-Founder & Vice Chairman)inStanley Lapidus(Director)inDawn Mattoon, PhD(Chief Executive Officer)Joseph Sedlak(Executive Officer, Director)
BoardPaul Meister(Director)Sonja Hoel Perkins(Director)in
Co-investorsAvestria VenturesiSelect FundMindshift CapitalNovalis LifeSciencesPortfoliaSozo Ventures+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.